
FDA approves Igalmi for at-home use for agitation in schizophrenia and bipolar disorder
Key Takeaways
- FDA authorization enables self-administration of dexmedetomidine sublingual film for acute agitation in schizophrenia, schizoaffective disorder, and bipolar I/II, representing a first-in-class at-home labeled option.
- Agitation affects an estimated 25%–40% of patients across these disorders and can rapidly escalate, with up to 21% of episodes leading to emergency care utilization.
The FDA cleared Teva’s Igalmi sublingual film for at-home use, the first at-home approved option for agitation tied to schizophrenia or bipolar disorder.
Adults with
Agitation symptoms associated with the above conditions may present as feelings of tension or increased activity. Igalmi is a 120 mcg, central alpha-2 adrenergic receptor agonist, which stops the brain from releasing the stress hormone norepinephrine. This lowers heart rate and blood pressure. Igalmi is available as sublingual film placed under the tongue or between the lower lip and gum. Teva said the approval makes it the first FDA-approved treatment for agitation associated with these conditions that can be used at home.
“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” Chris Fox, executive vice president, U.S. commercial and head of innovative franchise at Teva, said in the news release. “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it.”
Prevalence of agitation in schizophrenia and bipolar disorder
Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder affects between 25% and 40% of patients across these conditions, according to Teva. Acute episodes can escalate quickly, and in
Before this approval, patients experiencing agitation outside a clinical setting had no FDA-approved treatment option designed for self-administration at home.
What the SERENITY At-Home trial found
This approval was made using the results of the Phase 3 SERENITY At-Home Safety and Tolerability Trial, in which 1,160 agitation episodes in 102 patients were treated with Igalmi. Tolerability remained consistent with repeat dosing over the 12-week study period, and no patients discontinued Igalmi because of tolerability issues.
Side effects occurred in at least 5% of patients, the most common being somnolence, dry mouth and dizziness.
Igalmi carries warnings for patients with low blood pressure and slow heart rate. Patients are advised to drink fluids, sit or lie down after taking the film, and get up slowly to reduce the risk of fainting or falling. The label directs patients to tell their healthcare provider about heart problems, a history of fainting, low blood or fluid levels, diabetes, liver problems, and use of medicines that lower blood pressure or cause sleepiness, such as opioids.
Teva acquired Igalmi from BioXcel Therapeutics in late October. The application for at-home use was submitted in January 2026 as a supplemental New Drug Application to the existing Igalmi New Drug Application covering healthcare provider-supervised use.
What at-home approval of Igalmi could mean for payers
Moving treatment into the home could change where agitation episodes are managed. BioXcel previously estimated that patients experience 57 million to 77 million agitation episodes in the home setting each year in the United States, according to a company conference call on the trial results.
Teva has not disclosed pricing or a launch timeline and said it will announce commercialization plans for the at-home indication at a later date.
“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered,” Eric Hughes, M.D., Ph.D., executive vice president, global R&D and chief medical officer at Teva, said in the news release. “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”
Related to this article








